The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: infusion-related reaction associated with an immune checkpoint inhibitor
Parameters:
(1) severity of reaction
(2) therapy required
|
Severity
|
Therapy
|
Grade
|
|
mild and transient
|
none
|
G1
|
|
moderate but controllable
|
symptomatic; interruption of infusion prophylactic medication for <= 24 hours
|
G2
|
|
prolonged; recurrent; not controlled by symptomatic therapy
|
may require hospitalization
|
G3
|
|
life-threatening
|
urgent intervention required
|
G4
|
The diagnosis requires exclusion of other causes for the clinical reaction.
